CAJ | 학술논문

目的：比较R-CHOP方案与CHOP方案治疗早期初治胃弥漫大B细胞性淋巴（PG-DLBCL）的效果。方法回顾性分析2000年7月至2010年7月收治的65例早期初治PG-DLBCL患者的临床资料，其中R-CHOP组35例，CHOP组30例，比较两组患者的近期疗效、生存率及不良反应。结果 R-CHOP组完全缓解（CR）率为74.3%（26／35），CHOP组为50.0%（15／30）（P＜0.05），两组不良反应发生率差异无统计学意义（P＞0.05）。 Kaplan-Meier生存分析显示R-CHOP组5年生存率高于CHOP组（88.6%比75.0%），但两组差异无统计学意义（P＞0.05）；R-CHOP组无进展生存（PFS）优于CHOP组（94.4个月比74.9个月），两组差异有统计学意义（P＜0.05）。结论 R-CHOP方案治疗早期初治PG-DLBCL近期疗效较好，能够提高CR率，延长PFS，且不增加全身不良反应。
목적：비교R-CHOP방안여CHOP방안치료조기초치위미만대B세포성림파（PG-DLBCL）적효과。방법회고성분석2000년7월지2010년7월수치적65례조기초치PG-DLBCL환자적림상자료，기중R-CHOP조35례，CHOP조30례，비교량조환자적근기료효、생존솔급불량반응。결과 R-CHOP조완전완해（CR）솔위74.3%（26／35），CHOP조위50.0%（15／30）（P＜0.05），량조불량반응발생솔차이무통계학의의（P＞0.05）。 Kaplan-Meier생존분석현시R-CHOP조5년생존솔고우CHOP조（88.6%비75.0%），단량조차이무통계학의의（P＞0.05）；R-CHOP조무진전생존（PFS）우우CHOP조（94.4개월비74.9개월），량조차이유통계학의의（P＜0.05）。결론 R-CHOP방안치료조기초치PG-DLBCL근기료효교호，능구제고CR솔，연장PFS，차불증가전신불량반응。
Objective To compare the effect and safety of rituximab plus CHOP (R-CHOP) and CHOP regimens for the treatment of newly diagnosed patients with early-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL). Methods A total of 65 patients with PG-DLBCL were retrospectively divided into two groups: 35 patients were treated with R-CHOP regimen, the others with CHOP regimen. NHL international efficacy assessment and WHO criteria were used to assess the therapeutic and the adverse reactions respectively. Results The complete remission (CR) rate of R-CHOP group was 74.3 % (26/35), which was significantly higher than that of CHOP group [50.0 % (15/30), P< 0.05], but the adverse reactions rates of two groups had no significant difference (P>0.05). The Kaplan-Meier survival analysis showed that the five-year survival rates of two groups had no significant difference (88.6%vs 75.0%, P>0.05). The PFS of R-CHOP group was better than that of CHOP group (94.4 months vs 74.9 months, P< 0.05). Conclusion Compared with CHOP regimen , R-CHOP regimen increases the therapeutic efficacy in patients with PG-DLBCL, and dose not increase the adverse reactions.